Paul is co-founder and Chief Executive Officer of HairClone, a cell therapy Company developing cell based treatments for androgenic alopecia. Paul has over 30 years’ experience in the US and UK in the commercialisation of various Regenerative Medicine and Cell Therapy products in both public and private Companies. He was the lead inventor on patents for Apligraf the first multi-cell therapy approved by the FDA which has treated hundreds of thousands of patients in the US with chronic ulcers. Paul was the sole founder of Intercytex Ltd. where he served as CEO for the first 5 years. During this period Intercytex developed several products that reached the clinic, including Vavelta which was commercially available and being used for the correction of Rhytids, scar contractures and dystrophic epidermolysis bullosa before the EU’s ATMP regulations came into force. Intercytex also carried out the world's first cell therapy clinical trial to induce new hair formation. Paul has sat on a variety of panels, grant funding bodies and regulatory committees. He is co-editor of the Journal of Regenerative Medicine, a co-Director of the Doctoral Training Centre in Regenerative Medicine at Manchester University and Industrial Director of Regener8.

Rebecca joined the Entrepreneurship Centre to establish entrepreneurship education programmes for the research community at Cambridge. The first was EnterpriseTECH in 2018, which has seen over 400 PhD students and postdocs attend - working on over 75 commercialisation projects. She went on the create EnterpriseTECH STAR as follow-on programme which completed its first run in November 2019. Other programmes that fall within her remit include EnterpriseWOMEN and Enterprise Tuesday.

For close to 20 years, Rebecca’s home was the Department of Chemistry at the University of Cambridge. She is an organic chemist by training having done her PhD with Prof Chris Abell FRS. After her PhD, Rebecca went on to a long postdoc with Prof Steven Ley CBE FRS also in the Department of Chemistry. During this time, she also worked with Prof Sir Shankar Balasubramanian FRS as the Associate Director of the Cambridge-CRUK PhD Training Programme in Medicinal Chemistry for 10 years. Her research has covered many areas of chemistry, mostly at the medicinal chemistry interface, and particularly around cancer research. Rebecca values collaborative efforts and is passionate about cultivating meaningful research impact and creating opportunities for researchers to thrive beyond academia.

Aleksandra is Medical Director in Roche, leading innovative healthcare company, where she played key roles related to scientific research and market access in different therapeutic areas in Serbia and the region. She specialised programs INSEAD Roche Champions and London Business School 360.

Aleksandra finished School of Medicine in Belgrade with neurology specialisation and worked as a doctor at the Institute of Neurology, Clinical Center of Serbia, before she became part of pharma industry.

Dr Mellad is a scientist entrepreneur passionate about translating innovative technologies into better patient outcomes. As CEO and co-founder of Start Codon, he aims to identify and recruit the most disruptive healthcare start-ups across Europe, seed-fund them and drive their success. Previously, he was the CEO of Cambridge Epigenetix which has developed a proprietary epigenetic biomarker discovery platform for the development of new diagnostic assays and the identification of novel drug targets. While at Cambridge Epigenetix, Jason transformed the research tools company into a leading liquid biopsy player and led two successful fundraisers (Series B and C) for a total of $51m. Prior to joining Cambridge Epigenetix, Jason was a Business Development Manager for Horizon Discovery’s diagnostics division, being responsible for developing and launching new reference standards for genomic clinical assays. Jason obtained his PhD in Medicine from the University of Cambridge with a focus on the molecular mechanisms regulating vascular remodelling within coronary artery bypass grafts.

Laura obtained her PhD in Biotechnology in March 2015. During her PhD, she conducted research in new gene therapy applications in the field of cancer. Laura has worked in technology transfer managing projects in the health sector (diagnostics, pharmaceuticals, medical devices and ICTs) for the past two years. Nowadays, she is an investment analyst at Healthequity SCR and Invivo Ventures FCR, venture capital funds located in Barcelona, investing in SMEs in the Healthcare sector.

With 9y+ experience in marketing, Rita has been operatively involved in more than 20 startup projects as founder, marketer or freelancer. She is an expert in the field of early-stage growth, performance marketing and strategy focusing on startups. For 3 years, she has been acting as a mentor in 5 acceleration programs across Europe (incl. Techstars Berlin and StartupWiseGuys in the Baltics) and already coached 150+ tech startups (B2B and B2C). Currently she is the Head of Marketing at ZOLLHOF - Tech Incubator, one of the fastest growing startup incubators of Germany and officially the Digital Health Hub founded and backed by the German government. As part of the Digital Health Hub, Rita has been coaching digital health startups over the past couple of years.

Prior to his current role, Vincenzo was the Operation Officer and Chief of Staff for Enterprise Data & Analytics Programme, PMO director for Optimising Medical Evidence Generation Activities and Patient Centricity Excellence Director responsible for the strategic direction and delivery leadership of the overall capability programs to enable lifecycle teams to build patient value in R&D.

Following his passion for advancement of medicines for patients, before joining AstraZeneca, Vincenzo has led several projects at GlaxoSmithKline-UK in World Wide Business Development, in the Centres of Excellence for Drug Discovery, in Global Project & Portfolio Management and in Global Medical Affairs.

Vincenzo has contributed to several patented published inventions, successfully led the in-licensing of gene-therapy treatments and built the Global Strategy, Operations and Governance for a number of programmes in Global Medical Affairs, in Global Medicine Development and in BioPharmaceutical R&D within GlaxoSmithKline and AstraZeneca.
Vincenzo is a doctor in medicinal chemistry with an international Project Management accreditation and an MBA in strategic management.

Tony is an entrepreneur with exits and an authority on corporate innovation, entrepreneurship, start-ups, scaling and leveraging emerging technologies, capabilities and business models including circular economy. He is especially focused on Environment, Healthcare, Social Impact, purpose driven organisations.

He is currently a Board Member & Venture Partner of UNDP, International Trade Centre & Pfizer backed sustainability venture accelerator Accelerate2030 in Geneva that scales the impact of companies working towards positive social and environmental change aligned with the UN Sustainable Development Goals.

As an entrepreneur in residence with UK government’s Global Entrepreneur Programme he specialises in environmental, social impact, renewable energy and healthcare innovation combining positive impact with high commercial performance and access to finance for growth and scale at a global level.
Tony is active in research and academia and is a visiting lecturer and mentor at the University of Cambridge; Judge Business School, Entrepreneurship Centre, University of Cambridge; Department of Engineering, Institute for Manufacturing, INSEAD and the University of Cairo with focus on the UN SDG’s and the circular economy.

His corporate experience includes being a member of the Executive Board of T-Mobile International & Deutsche Telekom's corporate venturing T-Ventures as global EVP Business Development & Innovation and Group Managing Director of Bauer Digital for the €1.4bn M&A and post- merger integration of EMAP PLC. He has held senior international leadership positions in FMCG brand marketing (Nestle, Diageo).
His start-up and growth stage experiences include being the co-founder of mobile entertainment company Mobilephonia, leading the turnaround and sale of digital services agency Bluewave (Maersk portfolio) and the leadership team for an $800m IPO (NASDAQ: ACOM). He was co-founder and founding investor of accelerator Springboard (acquired by Techstars) and founder of Health-Tech Company Dupl (IP sale Optima), which provides context to biometric sensor data.

He is an investor and board advisor in mobile technology, digital media, nanotechnology, sustainability, CleanTech, HealthTech and software ventures with M&A exits to Oracle, Piksel, Nokia and Opentext.

Tony has an MBA from Henley Business School specialising in corporate venturing, BSc (Hon) Physics & Electronic Systems, from Brunel University, certified Neuro-Linguistic Programming (NLP) practitioner from University California, Santa Cruz and the Technische Universiteit Delft in Circular Economy.

Sina Henrichs has broad professional experience in implementation and development of projects in research-driven environments. She holds a doctorate in Molecular Biology from the University of Zurich as well as an MBA in Academic Management form the University of Basel. Sina Henrichs combines her extensive research experience in the life sciences and in-depth understanding of process development and project management to provide interactive and professional training experiences. She implemented the Graduate Center GRACE, the professional platform for doctoral candidates and postdocs at the University of Basel and is founder of Manage Science (www.managescience.ch). Since 2018, Sina is working as Project Manager Education at the AO Foundation in Davos.

Nick is a co-founder and CEO of Accunea Ltd, a medical device company with real time diagnostic monitoring products for patients with AKI and is the Director of Precision Medicine Strategy for New Medicine Partners, UK.

Nick has a PhD in Microbial Genetics from University of Warwick followed by post graduate research (genomics/biotechnology) at Harvard (DFCI, 1995) and Oxford (Biochemistry, 2000). At Oxford, the research in Professor Sir Ed Southern’s laboratory led to the creation of the spin out company Oxford Gene Technology Limited. Nick went on to secure a fellowship in technology transfer at the University of Warwick and then to Manchester as a business consultant to UMIC, mentoring entrepreneurs and commercial development of the bioincubator. This was followed by heading up the business group at Warwick HRI (2008) and the creation of Warwick Enterprise Park for provision of incubation facilities. Nick held several senior level positions as Scientist, CEO, NED, investor and Chairman in several start up enterprises such as the Oxford University start-up Oxagen (Human Genetics, 2003) Novolytics (antimicrobial therapeutics, 2010), BioMimox (peptide aptamers, 2014), Arcamis (business consulting, 2010), and has served as the Director of Business Development at OBN (2012). Nick has raised significant public, private, VC and business angel funding (Beer and Partners, 2013) for several businesses (multiple £M) and was a coach for the Growth Accelerator programme. More recently Nick created the Molecular Diagnostics Centre within the John Radcliffe Hospital, Oxford, building self-sustainability models and international collaborations and partnerships. Nick also led the successful bid to become the Oxford Genomics Medicine Centre and the Director of the Programme. Nick is a current member of the Diagnostics Advisory Council in Oxfordshire; has advised on Genomics products for ThermoFisher; was a lecturer at MIB (Manchester) in genomics; and graduated (2016) with a PGDiP in Strategy and Innovation from the Said Business School in Oxford.